NASDAQ: TER

TERADYNE, INC

CIK 0000097210 · Health Care · SIC 3825 · Instruments for Measuring

Large Revenue $3.2B Assets $4.9B as of Aug 1, 2026

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Sign up free

Want to see a complete report first? Today's free report (RBLX 10-Q) is open in full — no account needed.

10-Q Filed Jul 31, 2026 · Period ending Jun 28, 2026

Summary not yet generated.

8-K Filed Jul 29, 2026 · Period ending Jul 28, 2026

Summary not yet generated.

Partner

Trade TER commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed May 11, 2026 · Period ending May 8, 2026

Summary not yet generated.

10-Q Filed May 1, 2026 · Period ending Mar 29, 2026

Summary not yet generated.

8-K Filed Apr 29, 2026 · Period ending Apr 28, 2026

Summary not yet generated.

10-K Filed Feb 19, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-K Filed Feb 20, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed Jul 31, 2026 (period ending Jun 28, 2026). SEC XBRL (companyfacts) — not generated by the model.

SEC XBRL

Consolidated Statements of Operations (Unaudited)

Description Q2 ended Jun 28, 2026 Q1 ended Mar 29, 2026
Revenue:
Total revenue / net sales 1,329 1,282
Cost of revenue / cost of sales 534.4 501.5
Gross profit 794.6 780.9
Operating expenses:
Sales and marketing 102.6 98.1
Research and development 156.3 135.6
General and administrative 45.0 42.1
Selling, general and administrative 192.5 166.7
Total operating expenses 356.8 307.9
Operating income 437.8 473.0
Interest expense 3.0 3.2
Other income/(expense), net 5.6 (6.6)
Income before income taxes 443.6 465.7
Income tax expense/(benefit) 66.8 62.2
Net income 374.5 398.9
Basic earnings per share 2.39 2.55
Diluted earnings per share 2.38 2.53

Consolidated Balance Sheets (Unaudited)

Description Jun 28, 2026 Mar 29, 2026
Current assets:
Cash and equivalents 349.5 241.9
Accounts receivable, net 1,110 1,108
Inventories 65.5 44.8
Prepaid expenses and other current assets 30.0 18.7
Other current assets 811.3 760.2
Total current assets 2,366 2,173
Property, plant and equipment, net 634.8 585.7
Operating lease right-of-use assets, net 94.3 76.2
Finite-lived intangible assets, net 101.9 49.0
Goodwill 663.8 514.2
Deferred income taxes and other assets 289.6 281.8
Other long-term assets 775.1 753.8
TOTAL ASSETS 4,926 4,434
Current liabilities:
Line of credit
Accounts payable 383.4 344.7
Current portion of operating lease liabilities 17.3 18.4
Income taxes payable 164.9 173.3
Other current liabilities 547.9 475.8
Total current liabilities 1,114 1,012
Operating lease liabilities 82.9 64.0
Other long-term liabilities 255.9 213.8
Total liabilities 1,452 1,290
Shareholders' equity:
Common stock 19.5 19.6
Capital in excess of stated value 2,003 1,986
Accumulated other comprehensive income (loss) 10.8 20.4
Retained earnings (deficit) 1,404 1,118
Treasury stock 74.2 5.5
Total shareholders' equity 3,437 3,144
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 4,926 4,434

Consolidated Statements of Cash Flows (Unaudited)

Description Six months ended Jun 28, 2026 Q1 ended Mar 29, 2026
Operating Activities:
Net cash from operating activities 734.3 265.1
Investing Activities:
Net cash from investing activities (338.6) (67.3)
Financing Activities:
Net cash from financing activities (341.0) (250.2)
Net increase/(decrease) in cash 55.8 (51.8)

Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗